LGND logo

Ligand Pharmaceuticals Incorporated (LGND)

$279.44

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on LGND

Market cap

$5.60B

EPS

7.67

P/E ratio

31.2

Price to sales

16.75

Dividend yield

--

Beta

1.22143

Price on LGND

Previous close

$262.17

Today's open

$259.35

Day's range

$258 - $282.53

52 week range

$110 - $282.53

Profile about LGND

CEO

Todd C. Davis

Employees

47

Headquarters

Jupiter, FL

Exchange

NASDAQ Global Market

Shares outstanding

20041061

Issue type

Common Stock

LGND industries and sectors

Healthcare

Biotechnology & Life Sciences

News on LGND

Ligand Announces Pricing of Upsized $625 Million Convertible Senior Notes Offering

Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution to Ligand's common stock upon conversion of the notes JUPITER, Fla., June 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today the pricing of $625.0 million aggregate principal amount of 0.0% convertible senior notes due 2031 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”).

news source

GlobeNewsWire • Jun 23, 2026

news preview

Ligand Announces Proposed Offering of $550 Million of Convertible Senior Notes Due 2031

Opportunistic capital raise with proceeds used to enhance financial flexibility  A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution to Ligand's common stock upon conversion of the notes JUPITER, Fla., June 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) (“Ligand”) announced today its intention to offer $550.0 million aggregate principal amount of convertible senior notes due 2031 (the “notes”) in a private placement (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), subject to market conditions and other factors.

news source

GlobeNewsWire • Jun 22, 2026

news preview

Ligand Pharmaceuticals Director Unloads 2,501 Shares — Should You Be Concerned?

Kozarich sold 2,501 common shares. This transaction represented 5.65% of direct holdings.

news source

The Motley Fool • Jun 14, 2026

news preview

Ligand Announces 2026 Investor Day in New York City

JUPITER, Fla., June 10, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 8, 2026 at 10:30 a.m.

news source

GlobeNewsWire • Jun 10, 2026

news preview

A Ligand Pharmaceuticals (LGND) Insider Sold 5,000 Shares for $1.1 Million

5,000 shares were sold for a total transaction value of ~$1.14 million on June 1, 2026, at a weighted average price around $227.06 per share. This sale represented 10.78% of Andrew Reardon's direct Common Stock holdings, reducing direct ownership to 41,382 shares post-transaction.

news source

The Motley Fool • Jun 7, 2026

news preview

Ligand to Participate in June Investor Conferences

JUPITER, Fla., May 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its senior management team will participate in the following upcoming investor conferences: Stifel 2026 Boston Cross Sector 1x1 Conference.

news source

GlobeNewsWire • May 27, 2026

news preview

Saying Goodbye To The XOMA Royalty PFDs

Ligand Pharmaceuticals Incorporated will acquire XOMA Royalty Corporation for $39.00 per share in cash, totaling approximately $739 million. XOMA shareholders will receive a Contingent Value Right, or CVR, for 75% of net proceeds from certain pending litigation. The transaction is expected to close in Q3 2026 and be immediately accretive to LGND earnings per share.

news source

Seeking Alpha • May 25, 2026

news preview

Ligand Pharmaceuticals Incorporated (LGND) Q1 2026 Earnings Call Transcript

Ligand Pharmaceuticals Incorporated (LGND) Q1 2026 Earnings Call Transcript

news source

Seeking Alpha • May 9, 2026

news preview

Ligand Pharmaceuticals Q1 Earnings Call Highlights

Ligand Pharmaceuticals NASDAQ: LGND reported first-quarter 2026 results that management said reflect the operating leverage of its royalty aggregation strategy, highlighted by growing royalties from key commercial products and the pending acquisition of XOMA Royalty Corporation.

news source

MarketBeat • May 8, 2026

news preview

Ligand Reports First Quarter 2026 Financial Results

First quarter performance driven by strong year-over-year royalty revenue growth of  56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution from Pending XOMA Royalty Acquisition Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla.

news source

GlobeNewsWire • May 7, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Ligand Pharmaceuticals Incorporated

Open an M1 investment account to buy and sell Ligand Pharmaceuticals Incorporated commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in LGND on M1